Cardlytics (CDLX) Faces Investor Lawsuit Over Growth Projections - Hagens Berman
San Francisco, California--(Newsfile Corp. - January 31, 2025) - Cardlytics, the advertising technology company that connects marketers with consumers through their banking apps, is facing a class-action lawsuit alleging that it misled investors about its growth prospects. Hagens Berman urges Cardlytics, Inc. (NASDAQ: CDLX) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to...
2025-01-31 8:27 AM EST
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman
San Francisco, California--(Newsfile Corp. - January 30, 2025) - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct. 31, 2024, wiping out about $9 billion of market value. Hagens Berman has opened an investigation into whether Regeneron may have misled investors about its marketing and reimbursement practices related to its EYLEA® product, an injection to treat age-related macular degeneration by inhibiting...
2025-01-30 2:25 PM EST
Muddy Waters Report Triggers Lawsuit Against FTAI Aviation (FTAI) - Hagens Berman
San Francisco, California--(Newsfile Corp. - January 30, 2025) - FTAI Aviation Ltd. (NASDAQ: FTAI), a prominent aviation leasing and financing company, is facing a potential delay in filing its annual report for 2024 after a critical report from a well-known short-seller prompted an internal review. The company's disclosure caused the price of FTAI shares to decline 25%. Shareholder rights firm Hagens Berman urges FTAI Aviation investors to submit your losses now. Class Period: July 23, 2024...
2025-01-30 2:18 PM EST
Crocs, Inc. (CROX) Faces Securities Class Action over HEYDUDE Pipeline - Hagens Berman
San Francisco, California--(Newsfile Corp. - January 30, 2025) - Investors in Crocs, Inc. (NASDAQ: CROX) suffered yet another loss on Oct. 29, 2024 after the company prepared investors for disappointing Q4 and FY 2024 financial results that, in turn, sent shares crashing $26.47 (-19%). According to the company, the culprit was its HEYDUDE operating segment performance. Now a class action lawsuit has been filed focused on the propriety of Crocs' disclosures about sales practices within its...
2025-01-30 2:14 PM EST
Block, Inc. (XYZ) Faces Securities Class Action, Regulators Levy Cash App Fines Following Investigations Going Back to Hindenburg Report- Hagens Berman
San Francisco, California--(Newsfile Corp. - January 30, 2025) - Investors in Block, Inc. (NYSE: SQ) n/k/a (NYSE: XYZ) began to learn of potentially adverse information about the company and its Square and Cash App platforms on Mar. 23, 2023, when Hindenburg Research published a scathing report on the company. After a 2-year investigation, which included dozens of interviews with former employees, partners, and industry experts, Hindenburg concluded, in part, that Block had "wildly overstated...
2025-01-30 2:08 PM EST
BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman
San Francisco, California--(Newsfile Corp. - January 30, 2025) - BioAge Labs (NASDAQ: BIOA), a biopharmaceutical company focused on metabolic diseases, is facing a class-action lawsuit from shareholders who allege the company misled investors about the safety and prospects of a key drug candidate before its initial public offering last September. Hagens Berman urges investors who purchased BioAge shares in the company's IPO or on the open market and suffered substantial losses to submit your...
2025-01-30 2:01 PM EST
ASPI DEADLINE ALERT: ASP Isotopes (ASPI) Investors with Losses Encouraged to Contact Hagens Berman Before Feb. 3rd, 2025 Deadline in Securities Class Action
San Francisco, California--(Newsfile Corp. - January 29, 2025) - Shares of ASP Isotopes Inc. (NASDAQ: ASPI) have continue their downward spiral falling 16% over the past five days, despite the company having issued a rebuttal to a scathing report from activist short-seller Fuzzy Panda Research. The stock price trades at $4.52 per share, marking a 40% decline since the release of the short seller report late last month. The Fuzzy Panda report, published on November 26, accused ASP Isotopes of...
2025-01-29 1:45 PM EST
Symbotic (SYM) Accused of Misleading Investors with Inflated Revenues - Hagens Berman
San Francisco, California--(Newsfile Corp. - January 29, 2025) - Symbotic Inc. (NASDAQ: SYM), a Wilmington, Mass.-based automation technology company, has filed restated financial statements for three fiscal 2024 quarters, revealing significant errors in its previously reported revenue and profitability figures. The restatements, filed on December 4, follow the revelation of accounting errors last month and come as the company faces a securities fraud class action lawsuit. Hagens Berman has...
2025-01-29 1:43 PM EST
AstraZeneca (AZN) Reels from China Investigation and Investor Suit- Hagens Berman
San Francisco, California--(Newsfile Corp. - January 28, 2025) - AstraZeneca (NASDAQ: AZN), the Anglo-Swedish pharmaceutical giant, has seen its stock price tumble 15 percent over the past six months, buffeted by a series of unsettling reports emanating from China. A widening investigation by China regulators into alleged illegal drug imports, data breaches, and potential health insurance fraud has cast a shadow over the company's prospects in a critical market, triggering a securities class...
2025-01-28 2:22 PM EST
FTAI (FTAI) Faces Potential Delay in Filing Annual Report Amid Securities Class Action - Hagens Berman
San Francisco, California--(Newsfile Corp. - January 23, 2025) - FTAI Aviation Ltd. (NASDAQ: FTAI), a prominent aviation leasing and financing company, is facing a potential delay in filing its annual report for 2024 after a critical report from a well-known short-seller prompted an internal review. The company's disclosure caused the price of FTAI shares to decline 25%. Shareholder rights firm Hagens Berman urges FTAI Aviation investors to submit your losses now. Class Period: July 23, 2024...
2025-01-23 9:02 AM EST
BioAge Labs (BIOA) Faces Securities Class Action On Behalf Of IPO Investors After Discontinuing Weight-Loss Drug Trial- Hagens Berman
San Francisco, California--(Newsfile Corp. - January 23, 2025) - BioAge Labs (NASDAQ: BIOA), a biopharmaceutical company focused on metabolic diseases, is facing a class-action lawsuit from shareholders who allege the company misled investors about the safety and prospects of a key drug candidate before its initial public offering last September. Hagens Berman urges investors who purchased BioAge shares in the company's IPO or on the open market and suffered substantial losses to submit your...
2025-01-23 8:59 AM EST
Securities Class Action Allegations Cast Shadow Over Regeneron Pharmaceuticals (REGN)- Hagens Berman
San Francisco, California--(Newsfile Corp. - January 23, 2025) - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct. 31, 2024, wiping out about $9 billion of market value. Hagens Berman has opened an investigation into whether Regeneron may have misled investors about its marketing and reimbursement practices related to its EYLEA® product, an injection to treat age-related macular degeneration by inhibiting...
2025-01-23 8:56 AM EST
ASP Isotopes (ASPI) Accused of Deceiving Investors with Bogus Nuclear Tech Claims- Hagens Berman
San Francisco, California--(Newsfile Corp. - January 23, 2025) - Shares of ASP Isotopes Inc. (NASDAQ: ASPI) have continue their downward spiral falling 16% over the past five days, despite the company having issued a rebuttal to a scathing report from activist short-seller Fuzzy Panda Research. The stock price trades at $4.52 per share, marking a 40% decline since the release of the short seller report late last month. The Fuzzy Panda report, published on November 26, accused ASP Isotopes of...
2025-01-23 8:50 AM EST
SYM DEADLINE ALERT: Symbotic (SYM) Investors with Losses Encouraged to Contact Hagens Berman Before Feb. 3rd, 2025 Deadline in Securities Class Action
San Francisco, California--(Newsfile Corp. - January 23, 2025) - Symbotic Inc. (NASDAQ: SYM), a Wilmington, Mass.-based automation technology company, has filed restated financial statements for three fiscal 2024 quarters, revealing significant errors in its previously reported revenue and profitability figures. The restatements, filed on December 4, follow the revelation of accounting errors last month and come as the company faces a securities fraud class action lawsuit. Hagens Berman has...
2025-01-23 8:46 AM EST
AstraZeneca (AZN) Faces Securities Class Action After Reports of PRC Probe into Fraud and Corruption - Hagens Berman
San Francisco, California--(Newsfile Corp. - January 21, 2025) - AstraZeneca (NASDAQ: AZN), the Anglo-Swedish pharmaceutical giant, has seen its stock price tumble 15 percent over the past six months, buffeted by a series of unsettling reports emanating from China. A widening investigation by China regulators into alleged illegal drug imports, data breaches, and potential health insurance fraud has cast a shadow over the company's prospects in a critical market, triggering a securities class...
2025-01-21 3:55 PM EST
Muddy Waters Report Triggers Lawsuit Against FTAI Aviation (FTAI) - Hagens Berman
San Francisco, California--(Newsfile Corp. - January 21, 2025) - A class-action lawsuit has been filed against FTAI Aviation Ltd. (NASDAQ: FTAI) and certain of its executives, alleging securities fraud. The complaint, filed in the Southern District of New York, seeks to recover losses for investors who purchased FTAI securities between July 23, 2024, and January 15, 2025. Shareholder rights firm Hagens Berman is investigating the complaint's allegations and urges FTAI Aviation investors to...
2025-01-21 2:53 PM EST
BioAge Labs (BIOA) Faces Securities Class Action On Behalf Of IPO Investors After Discontinuing Weight-Loss Drug Trial- Hagens Berman
San Francisco, California--(Newsfile Corp. - January 14, 2025) - BioAge Labs (NASDAQ: BIOA), a biopharmaceutical company focused on metabolic diseases, is facing a class-action lawsuit from shareholders who allege the company misled investors about the safety and prospects of a key drug candidate before its initial public offering last September. Hagens Berman urges investors who purchased BioAge shares in the company's IPO or on the open market and suffered substantial losses to submit your...
2025-01-14 4:25 PM EST
AstraZeneca (AZN) Faces Securities Class Action After Reports of PRC Probe into Fraud and Corruption - Hagens Berman
San Francisco, California--(Newsfile Corp. - January 14, 2025) - AstraZeneca (NASDAQ: AZN), the Anglo-Swedish pharmaceutical giant, has seen its stock price tumble 15 percent over the past six months, buffeted by a series of unsettling reports emanating from China. A widening investigation by China regulators into alleged illegal drug imports, data breaches, and potential health insurance fraud has cast a shadow over the company's prospects in a critical market, triggering a securities class...
2025-01-14 4:23 PM EST
Analyst Downgrade Fuels Further Decline for Celsius (CELH) Shares Amid Sales Concerns and Investor Lawsuit- Hagens Berman
San Francisco, California--(Newsfile Corp. - January 14, 2025) - Shares of Celsius Holdings (NASDAQ: CELH), the energy drink maker already reeling from a 58 percent year-to-date decline, faced renewed pressure this month after a key analyst lowered its price target, citing concerns about sales and the impact of its distribution agreement with PepsiCo. This diminished valuation adds to the company's woes, which include slowing sales, revised financial forecasts, and a shareholder lawsuit...
2025-01-14 4:20 PM EST
Investors Sue PACS Group (PACS) Amid Accusations of Medicare Fraud - Hagens Berman
San Francisco, California--(Newsfile Corp. - January 10, 2025) - PACS Group (NYSE: PACS), a nursing home operator that saw its stock soar after its initial public offering in April, has experienced a precipitous decline in recent weeks, losing 70 percent of its market capitalization since early November. The company is now grappling with allegations of deceptive Medicare billing practices, a federal regulatory investigation, delayed financial reporting and a burgeoning investor class-action...
2025-01-10 9:16 AM EST